Adjuvant CMF-chemotherapy and haemostasis. Effect of 'classical' and 'modified' adjuvant CMF-chemotherapy on blood coagulation fibrinolysis in patients with breast cancer

European Journal of Gynaecological Oncology

Volumn 21, Issue 2, 2000, Pages 147-152

  Oberhoff, C ^b   Winkler, U H ^a   Hoffmann, O ^c   Schindler, A E ^c  

^a Friedrich Ebert Krankenhaus   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c NONE

Author keywords

Adjuvant chemotherapy; Breast cancer; Cyclophosphamide; Haemostasis; Protein C; Thrombosis

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 7; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PROTEIN C; PROTEIN S; VITAMIN K GROUP;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FIBRINOLYSIS; FLUOROURACIL; HEMOSTASIS; HUMANS; INFUSIONS, INTRAVENOUS; METHOTREXATE; MIDDLE AGED; PROBABILITY; STATISTICS, NONPARAMETRIC;

EID: 0034098460     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bonnadonna G., Brusamolino E., Valagussa P., Rossi A., Bugnatelli L., Brambilla C. et al.: "Combination chemotherapy as an adjuvant treatment in operable breast cancer". N. Engl. J. Med., 1976, 294, 405.
2. Bonnadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla Ch.: "Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer. The results of 20 years follow-up". N. Engl. J. Med., 1995, 332, 901.
3. Clahsen P. C., van der Velde C. J. H., Julien J. P., Floiras J. L., Mignolet F. Y. et al.: "Thromboembolic compliations after perioperative chemotherapy in women with early breast cancer: A European Organisation for Research and Treatment of Breast Cancer Cooperative Group Study". J. Clin. Oncol., 1994, 12, 1266.
4. Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W. et al.: "The thombogenic effect of anticancer drug therapy in women with Stage II breast cancer". N. Engl. J. Med., 1988, 318, 404.
5. Perloff M., Lesnick G. J., Korzun A., Chun F., Holland J. F., Thrilwell M. P. et al.: "Combination chemotherapy with mastectomy or radiotherapy for stage III breast cancer: A cancer and leukemia group B study". J. Clin. Oncol., 1988, 6, 261.
6. Saphner T., Tormey D. C., Gray R.: "Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer". J. Clin. Oncol., 1991, 9, 286.
7. Pritchard K. I., Paterson A. H. G., Paul N. A., Zee B., Fine S., Pater J. for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group: "Increased thromboembolic compliations with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer". J. Clin. Oncol., 1996, 14, 2731.
8. Goodnough L. T., Saito H., Manni A., Jones P. K., Pearson O. H.: "Increased incidence of thromboembolism in Stage IV breast cancer patients treated with a five-drug chemotherapy regime - a study of 159 patients". Cancer, 1984, 54, 1264.
9. Levine M. L.: "Double-blind randomized trial of very low warfarin for prevention of thromboembolism in stage IV breast cancer". Lancet, 1994, 343, 886.
10. Cannobio L., Fassio T., Ardizzoni A., Bruzzi P., Querirolo M. A., Zarcone D. et al.: "Hypercoagulable state induced by cytotoxic drugs in stage II breast cancer patients". Cancer, 1986, 58, 1032.
11. Feffer S. E., Carmosino L. S., Fox R.: "Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5-fluorouracil". Cancer, 1989, 63, 1303.
12. Rogers II J. S., Murgo A. J., Fontana J. A., Raich P. C.: "Chemotherapy for breast cancer decreases plasma protein C and protein S". J. Clin. Oncol., 1988, 6, 276.
13. Relia C., Coviello M., Giotta F., Maiello E., Colavito P., Colangelo D.: "A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy". Breast Cancer Res. Treat., 1996, 50, 73.
14. Moore M. J.: "Clinical pharmacokinetics of cyclophophamide". Clin. Pharmacokinet., 1991, 20, 194.
15. Juma F. D., Rogers H. J., Tounce J. R.: "Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration". Br. J. Clin. Pharmac., 1979, 8, 209.
16. Engelsman E., Klijn J. C. M., Rubens R. D., Wildiers J., Beex L. V. A. M., Nooij M. A.: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC breast cancer co-operative group phase III trial (10808)". Eur. J. Cancer, 1991, 27, 966.
17. Jespersen J., Bertina R. M.: "ECAT Assay Procedures". Haverkate, Kluwer Academic Publishers, 1982.
18. Kluft C., Verheijen J. H.: "Leiden fibrinolysis working party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1)". Fibrinolysis, 1990, 4, Suppl. 2, 155.
19. Kluft C., Meijer P.: "Update 1996: Blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop)". Fibrinolysis, 1996, 10, Suppl. 2, 171.
20. SAS Institute Inc.: "SAS User's Guide Statistic". Version 5 Edition. Cary, NC: SAS Inst Inc., 1985.
21. Aillaud M. F., Roul C., Elias E., Bouvier J. L., Serradimigni, Juhan-Vague I.: "Clinical relevance of plasma fibrin degradation products determination in patients with deep vein thrombosis". Thromb. Haemost., 1987, 58, 332.
22. Graeff H., Hafter R.: "Detection and relevance of crosslinked fibrin derivates in blood". Semin. Thromb. Haemost., 1982, 8, 57.
23. McCulloch P., Nieuwenhuizen W., Douglas J., Lowe G. D. O., George W. D.: "Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin-fibrinogen degradation products". Hameostasis, 1990, 20, 73.
24. Esmon C. T.: "Protein C.: Biochemistry, physiology and clinical implications". Blood, 1983, 62, 1155.
25. Esmon C. T., Owen W. G.: "Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C". Proc. Natl. Acad. Sci. USA, 1981, 78, 2249.
26. Dahlhäck B.: "The protein C anticoagulant system: Inherited defects as a basis for venous thrombosis". Thromb. Res., 1995, 77, 1.
27. Finazzi G., Barbui T.: "Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S". Thromb. Haemost., 1994, 71, 15.
28. Hyman J., Zimmerman J. H.: "Hepatotoxic effects of oncotherapeutic agents". Prog. Liver. Dis., 1990, 7, 621.
29. Wooly P. V.: "Hepatic and pancreatic damage produced by cytotoxic drugs". Cancer Treat. Rev., 1983, 10, 117.